Moderna Announces First Patient Dose in mRNA-3705 Phase 1/2 Study for Methylmalonic Acidemia (MMA).
Moderna, Inc., a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that the first patient had been enrolled in the Phase 1/2 study evaluat ...
Moderna’s mRNA-1345 Receives Breakthrough Designation from FDA for Respiratory Syncytial Virus (RSV) Prevention
Moderna, a biotechnology company pioneering mRNA therapeutics and vaccines, announced that mRNA-1345, its investigational mRNA vaccine for respiratory syncytial virus (RSV), has received Breakthrough ...